Retinal screening programmes in England and Scotland have similar photographic grading schemes for background (non-proliferative) and proliferative diabetic retinopathy, but diverge over maculopathy. We looked for the most cost-effective method of identifying diabetic macular oedema from retinal photographs; including the role of automated grading and optical coherence tomography, a technology that directly visualises oedema.
INTRODUCTION
Diabetic retinal screening programmes in the United Kingdom differ over how surrogate photographic markers are used to screen patients for diabetic macular oedema. England utilises exudates within two disc diameters of the centre of the macula and, if visual acuity is reduced, blot haemorrhages and microaneurysms/dot haemorrhages within one disc diameter. Scotland only utilises exudates and blot haemorrhages within one disc diameter, regardless of the visual acuity.
We investigated the accuracy and cost-effectiveness of these schemes using optical coherence tomography (OCT), a technology that directly visualises oedema, as the reference standard. Additionally we investigated the accuracy and cost-effectiveness of automated grading and the role of OCT in screening for diabetic macular oedema. [1] [2] [3] 
MATERIALS AND METHODS
This was a multi-centre, prospective, observational cohort study. Participants with diabetes were recruited from retinopathy screening and ophthalmology in Aberdeen, Birmingham, Dundee, Dunfermline, Edinburgh, Liverpool and Oxford.
Patients aged 18 or older who gave informed consent were included. The following photographic features in at least one eye were required for recruitment: microaneurysms/dot haemorrhages or blot haemorrhages within one disc diameter, exudates within one or two disc diameters of the centre of the macula. Exclusions were: pregnancy; contra-indications to dilatation; intraocular surgery within one year; macular or pan-retinal laser treatment; or intraocular injection. The reference standard was an adequate OCT image of both eyes. Patients were omitted from analysis if they had an inadequate OCT image in either eye. Patients with an adequate retinal photograph in one eye were included.
To avoid inter-centre variation, OCT operators submitted a portfolio of images for accreditation.
A 45º macula-centred colour digital retinal photograph (3-8 megapixels, with or without JPEG compression) was obtained from each eye. OCT images were obtained from each eye producing a nine subfield "Early Treatment of Diabetic Retinopathy Study" (ETDRS) map showing average regional thickness, and a horizontal cross-section through the centre of the macula or the region of greatest thickness. [4] The outer four regions were disregarded. Best logMAR visual acuity was recorded unaided, with pinhole or with glasses. There was a maximum of 4 weeks between photograph and OCT scan.
All images were graded and annotated by a quality assured grader (94·3% sensitivity, 95·7% specificity, for referable retinopathy/maculopathy, 2012 [5] ) prior to reviewing the OCT data Borderline images were referred to a senior ophthalmologist.
Diabetic macular oedema was deemed present if:
 Central ETDRS region thickness >250 µm or any of inner five regions >300 µm;
 AND visible intra-retinal cyst or area of sub-retinal fluid on OCT crosssection;
 AND no other visible cause for macular oedema e.g. vein occlusion.
Thickness thresholds were adjusted to account for all scanners used in the study. [3] 
Grading Schemes
England's, Scotland's and a hybrid scheme, utilising features from both, were assessed (Table 1) .
A fully automated grading scheme was developed utilising existing software. [6, 7] Automated inputs included: image feature intensity; image clarity; counts of microaneurysms/dot haemorrhages within one disc diameter and two disc diameters; likelihoods of haemorrhages within one disc diameter and anywhere in the image; likelihoods of exudates within one disc diameter, two disc diameters and anywhere in the image; and visual acuity. To identify sampling bias, patients were classified into a hierarchy of five mutually exclusive categories of features present in either eye:
1. Exudates within one disc diameter.
2. Blot haemorrhages, but no exudates, within one disc diameter.
3. Microaneurysms/dot haemorrhages, but no exudates or blots, within one disc diameter.
Exudates within one -two disc diameters with no relevant diabetic
retinopathy features within one disc diameter.
None of the above.
Weighting was undertaken to correct for sampling bias, based on observed proportions of the above categories in a consecutive cohort of 6,900 patients attending retinal screening in Grampian. [8, 9] Each weight [10] [11] [12] was calculated as the ratio of the observed proportion in the cohort study [9] to that in the present study.
For both weighted and unweighted data, the sensitivity and specificity of using each investigated scheme were estimated at the patient level. [13] For these calculations, referral of the patient corresponded to a scheme applied to both eyes separately indicating referral in either eye (or both). The analysis simulated the passage of 100,000 "patients", with characteristics matching those of patients in the clinical dataset, through the model individually.
Cost Effectiveness Analysis
As above, the proportions of patients in the different feature categories were weighted. The impact of using alternative grading schemes within annual screening was assessed by applying the weighted sensitivities and specificities within the model. Modelling was also used to assess the cost per case of macular oedema detected from one round of screening for this cohort (see appendix).
The mean costs, years free of moderate visual loss (in either eye) and quality adjusted life years accruing to patients, under the alternative grading schemes, were compared to estimate incremental cost-effectiveness ratios (ICERs). The schemes were compared both with and without the use of OCT prior to referral.
We also assessed a scheme (Scheme A) whereby anyone with markers of diabetic maculopathy would be examined with OCT. A ceiling willingness to pay ratio of £30,000 per QALY gained was applied to identify the optimal scheme on grounds of cost-effectiveness. [19] To characterise the uncertainty surrounding the cost-effectiveness of alternatives, deterministic and probabilistic sensitivity analyses were undertaken. The probabilistic analysis sampled from distributions assigned to each model parameter, and simulated the passage of 10,000 patients through the model 1000 times. This produced 1000 estimates of the mean cost and effects for each scheme. Cost-effectiveness acceptability curves were produced by calculating the proportion of these iterations favouring each of the schemes (on grounds of cost-effectiveness) at different ceiling ratios of willingness to pay per QALY. [20] The methods used to derive probabilities for visual loss and the development of macular oedema precluded determination of the statistical impression surrounding these estimates. The impact of variation in these parameters was addressed through deterministic sensitivity analysis. When mutually exclusive categories of lesions were considered, diabetic macular oedema was present in 14·1% of those with exudates within one disc diameter;
RESULTS
12·1% of those with blot haemorrhages (but no exudates within one disc diameter); and 3·2% of those with microaneurysms/dot haemorrhages (and no exudates or blot haemorrhages within one disc diameter) ( Table 2) . Table 3 shows the analysis weights used to correct for sampling bias. Exudates within one disc diameter and blot haemorrhages were down weighted. Exudates between one and two disc diameters and microaneurysms/dot haemorrhages were up weighted. Table 4 shows the sensitivities and specificities for predicting the presence of diabetic macular oedema from certain lesion combinations for unweighted and weighted data. The presence of exudates within one disc diameter had the greatest influence on the prediction of macular oedema. The addition of exudates between one -two disc diameters did not identify any further cases (Table 4 ). and specificity of 79%. The hybrid scheme had sensitivity of 73·3% and specificity of 70·9% ( Table 5 ).
The receiver operating characteristic curve for automated grading is shown in Figure 3 together with the sensitivities and specificities for the three manual schemes. Compared to the manual schemes, for the same sensitivity, automated grading achieved a higher specificity. The automated system operating point used in the cost-effectiveness analysis had slightly higher sensitivity (75·9%) and specificity (73·7%) than the hybrid manual grading scheme ( Table 5 ).
The results of the short term analysis of the cost per case detected from one round of screening are presented in the web appendix. Table 6 shows the results of the cost-effectiveness analysis. The addition of OCT to each scheme resulted in cost-savings without reducing health benefits.
Scotland's scheme was found to be most cost-effective at the accepted ceiling ratio of £30,000 per QALY, with or without the addition of OCT. Even scheme A, where any one with markers of diabetic maculopathy is examined with OCT, produces cost savings over all the manual schemes without OCT.
In the study, automated grading had higher specificity but similar sensitivity to England's and the hybrid scheme ( Figure 3 ). Assuming that automated grading was implemented for a similar cost to manual grading, it has the potential to produce a similar number of QALYs, but at a lower overall cost to the health service, than either England's or the hybrid scheme. Automated grading could be made cost-effective in Scotland, but an operating point at a higher specificity would have to be chosen.
Deterministic sensitivity analysis suggested that monitoring patients with suspected diabetic macular oedema (on a 6-monthly basis) with OCT and retinal photography remained cost saving up to an incremental cost of ~£58 per patient. Further scenario analyses assessed the sensitivity of findings to alterations in assumptions and parameters in favour of the more sensitive and less specific strategies (see web appendix). Only when a number of parameters were simultaneously weighted in favour of the more sensitive strategies, did incremental cost per QALY approach the accepted threshold range (£20-30,000
per QALY). in favour of the more sensitive schemes, the additional costs of these schemes (per QALY gained) remained above thresholds for cost-effectiveness. [19] With weighted data, automated grading (working at any operating point on its receiver operating characteristic curve) improved performance over the manual schemes. Cost effectiveness will depend on the operating point chosen, the costs of implementation, balanced against cost savings resulting from reductions in manual grading time and unnecessary referrals. [9] In this study, a variety of OCT scanners were used. A variation in detection of diabetic macular oedema between centres was noted, partly due to differences in the sensitivity of the scanner and partly due to case-selection. Cases missed by less sensitive scanners may have biased the estimated sensitivities and specificities, but most likely in the same directions for all schemes. Hence they are unlikely to have affected the broader inferences.
Economic modelling suggests that the use of OCT in conjunction with photography within screening programmes, for patients with surrogate markers of oedema, is likely to be cost-effective. The estimated marginal cost of conducting OCT within the screening programme (£32) is low in comparison with the cost of referral to ophthalmology (£143) and consequent monitoring in the outpatient setting. As the analysis included a survey of costs and pathways of implementation in the participating centres the results can be applied across England and Scotland.
We assumed that patients without treatment would progress at the rate observed in the Early Treatment Diabetic Retinopathy Study. [14] To assess the benefits of improved detection and referral, the best available evidence was used. [4, 14, 15] Although Ranibizumab has now been approved, [21] its impact on the cost-effectiveness of screening for macular oedema is unknown.
Considering the comparison of alternative photographic grading schemes in England and Scotland for triggering referral to ophthalmology or an OCT examination, we found Scotland's scheme to be preferred based on weighted data when applying a ceiling ratio of £30,000 per QALY gained.
Automated grading benefits from the ability to choose different operating points, depending on the sensitivity desired. At the study's chosen operating point, if it could be implemented without increasing grading costs, automation could produce a similar number of QALYS for a lower overall cost than England's scheme. Automated grading could be made cost-effective in Scotland, but an operating point at a higher specificity would have to be chosen.
Utilising optical coherence tomography, as part of the screening pathway, could reduce costs to the health service.
Retinal screening programmes in the United Kingdom should reconsider the screening pathway to make best use of existing and new technologies.
Figure legends:
FIGURE 1 Study design for recruitment, with hybrid manual grading scheme as the diagnostic test and with the reference standard of macular oedema presence. "Positive" means that the image was judged to have macular oedema. "Positive" means that the image was judged to have macular oedema. 
